Key Insights• According to the research report, "UAE Antacids Market Outlook, 2031," published by Actual Market Research, the UAE Antacids Market is anticipated to grow at more than 5.91% CAGR from 2026 to 2031.• The demand for antacids and gastrointestinal relief in the UAE is uniquely amplified by high rates of lifestyle-related metabolic risk factors, late-night dining habits, and a fast-paced urban environment across major hubs like Dubai and Abu Dhabi. Regional epidemiological studies indicate that the prevalence of Gastroesophageal Reflux Disease (GERD) in the UAE adult population is approximately 13.5%, rising significantly to 19.2% among adults over 30 years old.• Traditional single-salt antacids (such as standard calcium carbonate alone) are increasingly yielding shelf space to advanced multi-action raft-forming products. Innovation in the UAE retail market is led by alginate-antacid combination therapies (such as Gaviscon Double Action variants). These formulations utilize sodium alginate to form a physical protective barrier over stomach contents within minutes while simultaneously buffering stomach acid, offering faster relief for nocturnal and post-meal reflux.• The UAE represents one of the most digitally mature OTC healthcare markets in the Middle East, driven by rapid urbanization and high smartphone penetration. Digital pharmacy orders and quick-commerce OTC delivery platforms (such as InstaShop, Noon Pharmacy, Talabat Mart, and chain e-pharmacies) have seen digital OTC sales grow by over 30%.Market Outlook• Future OTC product launches in the UAE are expected to feature dual-action solutions combining immediate acid neutralizers with targeted gut-microbiome probiotics to manage both short-term acidity and long-term digestive wellness. Under the UAE's national industrial strategy (Operation 300bn), local drugmakers are expanding domestic production of OTC gastrointestinal line extensions to reduce reliance on imported pharmaceutical brands and ensure localized supply chain resilience.• The regulatory framework is governed by the UAE Ministry of Health and Prevention (MOHAP) and the Dubai Health Authority (DHA), with market commercialization led by major global and regional healthcare leaders including Reckitt Benckiser (Gaviscon), Bayer Middle East (Rennie, Alka-Seltzer), GSK / Haleon, Julphar (Gulf Pharmaceutical Industries), and Sanofi (Maalox).Market DynamicsDriver: Population growth, immigration and increasing digestive-health demandA major driver for the UAE antacids market is the country's rapidly expanding and highly international consumer base.

The UAE has a large expatriate population, continued immigration and a steady flow of international tourists. Euromonitor identifies rising immigration, population growth and continuous tourist inflows as structural factors supporting consumer-health demand in the UAE. For antacids specifically, this creates a broad and diverse consumer base exposed to different dietary habits, eating schedules and lifestyles.Challenge: Fragmented competition and substitution from broader digestive remediesThe main challenge is the highly fragmented competitive environment. Euromonitor describes the UAE digestive-remedies market as highly fragmented, with consumers having access to antacids alongside IBS treatments, digestive enzymes, antiflatulents, H2 blockers and proton-pump inhibitors (PPIs). This means antacids are not competing only against other antacid brands. Consumers with recurring reflux may choose longer-acting acid-suppression products, while consumers with milder or broader digestive complaints may select enzymes, probiotics or other digestive-health products.Trend: Shift toward specialized digestive-health solutions and pharmacist-led recommendationsA significant trend is the move from basic symptom relief toward specialized digestive-health products.

Euromonitor identifies rising IBS rates as an opportunity for specialized solutions and notes that consumers place considerable trust in pharmacists for digestive-health recommendations. It also highlights opportunities to address the needs of young adults and women and consumers taking a longer-term approach to digestive health. This creates opportunities for antacid manufacturers to move beyond conventional acid-neutralizing products and develop combination formulations, targeted reflux solutions and convenient formats.Segment AnalysisUAE Antacids Market By Drug Class• Acid neutralizers remain closely associated with rapid, on-demand relief in the UAE because they directly neutralize gastric acid rather than primarily suppressing future acid production. Calcium carbonate, magnesium hydroxide and aluminium hydroxide-based preparations can address occasional heartburn, acid indigestion and acid-related discomfort. Their role is particularly suited to consumers seeking immediate symptom management. The UAE's regulatory framework explicitly recognizes OTC medical products and regulates their sale, storage and circulation outside conventional pharmaceutical establishments.• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-control position because they suppress gastric acid secretion and are more appropriate for recurring reflux symptoms and clinically established acid-related disorders.

This creates a different purchasing pattern from conventional antacids: consumers with occasional symptoms may favor rapid-relief products, whereas people experiencing recurrent symptoms may transition toward longer-acting acid suppression under pharmacist or physician guidance. UAE pharmacies operate within a regulated pharmaceutical framework, with OTC and prescription medicines separately classified.• H2 antagonists provide an intermediate acid-suppression approach by reducing acid secretion through H2-receptor blockade. They can appeal to consumers seeking longer symptom control than conventional acid neutralizers without necessarily moving to continuous PPI treatment. Their positioning is particularly relevant where pharmacists help consumers distinguish occasional heartburn from symptoms that may require medical assessment.• Pro-motility agents represent a specialized gastrointestinal segment because their principal action is directed toward gastrointestinal movement rather than acid neutralization. They can become relevant when reflux symptoms coexist with delayed gastric emptying, post-meal fullness or motility disturbances. Their use is therefore more clinically directed than conventional OTC antacid consumption.• Combination formulations are particularly relevant in the UAE because consumers may experience several gastrointestinal complaints simultaneously, including heartburn, acid reflux, bloating and gas.

Antacid-alginate combinations can combine acid neutralization with a physical reflux barrier, while antacid-plus-simethicone products can address gas-related discomfort. Multi-symptom positioning allows manufacturers to differentiate products in a mature self-care category.UAE Antacids Market By Dosage Form• Tablets and chewables are well suited to the UAE's pharmacy-led self-care environment because they provide portable, standardized dosing and can be used without measuring equipment. Chewables are particularly convenient after meals, during work or while travelling. Their portability is also relevant in a country with a highly mobile population and substantial consumer reliance on community pharmacies.• Liquid suspensions provide an important alternative for consumers who have difficulty swallowing tablets or prefer liquid medicines. They allow manufacturers to formulate aluminium- and magnesium-based combinations and can provide a distinctive sensory experience. Accurate measuring, shaking requirements, flavour and storage stability are important because UAE consumers may encounter products across both pharmacy and non-pharmacy retail settings.• Powders provide a flexible format that can be packaged in individual sachets and prepared immediately before use.

Their portability can make them attractive for consumers who want to carry a single-dose product. However, preparation requirements create a convenience disadvantage compared with ready-to-use liquids and chewables, making packaging and clear Arabic/English instructions particularly important in the UAE.• Gels and syrups emphasize smooth administration and can support formulations designed around reflux-barrier mechanisms. Alginate-based gels are particularly relevant because they can create a physical barrier that limits movement of gastric contents toward the oesophagus. Syrup-like products can additionally differentiate through flavour and ease of swallowing.• Gummies and other formats represent a more consumer-oriented opportunity within the UAE digestive-health category. Gummies offer portability and familiar administration, but traditional antacid ingredients can be challenging to incorporate at therapeutically useful quantities while maintaining acceptable taste and texture. Effervescent and rapidly dispersible formats can therefore provide alternative convenience-focused positioning.UAE Antacids Market By Indication• Gastroesophageal Reflux Disease (GERD) is an important indication supporting the UAE acid-control category because recurring reflux symptoms can move consumers from occasional antacid use toward H2 antagonists or PPIs.

The UAE's urban lifestyle, dietary diversity and strong private-healthcare infrastructure create an environment where both consumer self-care and physician-directed reflux management are relevant. Products therefore need clear differentiation between occasional symptom relief and longer-term acid control.• Heartburn is one of the strongest consumer-facing indications because it is readily recognizable and can encourage direct pharmacy purchases. Antacids provide an attractive option when symptoms are occasional and consumers want rapid relief. For persistent or recurrent symptoms, pharmacist intervention becomes more important because repeated self-treatment can indicate an underlying reflux disorder requiring evaluation.• Peptic ulcer represents a more medically managed indication than routine heartburn. Antacids can reduce acid-related discomfort but do not eliminate underlying causes such as H. pylori infection or NSAID-associated mucosal injury. Consequently, PPIs and cause-directed treatment have a stronger role in ulcer management, while conventional antacids are primarily positioned for symptomatic relief.• Others include dyspepsia, acid indigestion, epigastric discomfort, gastritis-related symptoms, bloating and post-meal fullness.

This segment is important because consumers may interpret a wide range of upper-GI symptoms as simple acidity. Multi-symptom formulations therefore have an opportunity to address broader digestive discomfort rather than focusing exclusively on gastric acid.UAE Antacids Market By Distribution Channel• Retail pharmacies remain strategically important because consumers can obtain OTC products while accessing pharmacist advice. The UAE's pharmaceutical legislation formally distinguishes prescription and non-prescription medical products, while Dubai Health Authority states that the country's medication system includes OTC, pharmacist-only and prescription-only categories. This makes pharmacist guidance particularly valuable when consumers are deciding between antacids, H2 antagonists and PPIs.• Hospital pharmacies serve a more clinically supervised segment involving patients with diagnosed GERD, reflux complications, peptic ulcers and other gastrointestinal conditions. Demand through this channel is therefore more influenced by physician diagnosis, hospital formularies and treatment protocols than by spontaneous OTC purchasing. UAE hospital pharmacy standards specifically recognize OTC medicines alongside prescription and pharmacist-only medicines within the pharmaceutical environment.• Online pharmacies / E-commerce provide an increasingly relevant route for repeat purchases because consumers can compare products, pack sizes and dosage forms and reorder familiar medicines without visiting a physical pharmacy.

The UAE has specifically introduced regulation covering electronic sale and circulation of non-prescription medical products in non-pharmaceutical establishments, demonstrating that digital OTC distribution is now incorporated into the country's regulatory framework.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Antacids Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Drug Class• Acid Neutralizers• Proton Pump Inhibitors (PPIs)• H2 Antagonists• Pro-Motility Agents• Combination FormulationsBy Dosage Form• Tablets & Chewables• Liquid Suspensions• Powders• Gels & Syrups• Gummies & OtherBy Indication• Gastroesophageal Reflux Disease• Heartburn• Peptic Ulcer• OthersBy Distribution Channel• Retail Pharmacies• Hospital Pharmacies• Online Pharmacies / E-Commerce.